• Ikonisys signed strategic memorandum of understanding with Cellay to combine automation platform with Same Day OligoFISH probes for urology-focused cancer diagnostics, targeting faster rollout in US market.
• Deal shifts business model toward recurring revenue, with Ikonisys set to earn royalties on sales of Cellay reagents tied to deployed systems.
• Cellay to support commercialization of Ikonisys and Hospitex solutions in US; Aliko Scientific to distribute Cellay products outside US.
• Partnership launched with first US commercial customer agreement with Arizona Urology Specialists, part of United Urology Group and OneOncology network, to deploy Ikoniscope Low Volume Test for automated FISH bladder cancer screening and monitoring using Cellay probes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikonisys SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260511347150) on May 11, 2026, and is solely responsible for the information contained therein.